Sign Up
Stories
CARMAT's Advancements in Artificial Heart Technology
Share
BiVACOR Appoints New Chairman
BiVACOR Welcomes New CEO and FDA Approva...
CARMAT's 2024 Financial Calendar and Hea...
AI-Powered Raspberry Pi Stethoscope Inno...
Overview
API
CARMAT, a company specializing in the Aeson® artificial heart, has achieved a milestone of 50 implants and presents its development prospects. The company has seen significant advancements in sales and safety profile, aiming to provide a therapeutic alternative for patients with advanced heart failure.
Ask a question
How does the software enhancement for Aeson® contribute to its safety profile and potential commercial success?
How might the advancements in Aeson® technology impact the treatment of heart failure?
What challenges might the expansion of therapy on a large scale present for CARMAT?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Coverage